{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 49,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a hub-and-spoke diagram to illustrate the negative consequences of neurotoxicity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/7",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.85,
        "x": 0.08,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Neurotoxicity (in all approved and late clinical stage BCMA CAR-Ts) connected to Parkinson's Like Symptoms, Long Hospital Stay, Limited Hospital Access, and Death.",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "106ee3a3-5661-4ee8-91fd-69d5b761a34e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.4,
        "y": 0.65
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7256e90f-32b1-4881-a273-80a68a5a8ec1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.02,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Carvykti FDA label; Abecma FDA label; AAMC (Association of American Medical Colleges); Sharma, A., Singh, V., & Deol, A. (2023). Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients. Transplantation and cellular therapy, 29(2), 108.e1–108.e7. https://doi.org/10.1016/j.jtct.2022.11.004",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d1a6921-3694-4756-a382-27441951c36c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "Current Problems of Administering BCMA CAR-T: Neurotoxicity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35383efc-1296-437a-af78-7aa000fe00c7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "1d3eaf9a-7b60-4816-8c7e-cd036241acc0",
      "evidence": "Central node (Neurotoxicity) connected to four peripheral problem nodes.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 7,
      "from": 5,
      "beatId": "4b86493a-1393-464b-b6ad-158ad0028028",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Discussion of current problems with BCMA CAR-T therapies",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
      "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
      "position": 0,
      "objective": "Highlighting the need for improved therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}